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BACKGROUND. The genetic basis of susceptibility to prostate cancer (PRCA) remains
elusive. Mutations in BRCA2 have been associated with increased prostate cancer risk and
account for around 2% of young onset (<56 years) prostate cancer cases. PALB2 is a recently
identified breast cancer susceptibility genewhose protein is closely associatedwith BRCA2 and
is essential for BRCA2 anchorage to nuclear structures. This functional relationship made
PALB2 a candidate PRCA susceptibility gene.
METHODS. WesequencedPALB2 inprobands from95PRCA families, 77 ofwhich had twoor
more cases of early onset PRCA (age at diagnosis<55 years), and the remaining 18 had one case
of early onset PRCA and five or more total cases of PRCA.
RESULTS. Two previously unreported variants, K18R and V925L were identified, neither of
which is in a known PALB2 functional domain and both of which are unlikely to be pathogenic.
No truncating mutations were identified.
CONCLUSIONS. These results indicate that deleterious PALB2mutations are unlikely to play
a significant role in hereditary prostate cancer. Prostate 68: 675–678, 2008. # 2008Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer is a leading cause of morbidity and
mortality in men and it is diagnosed in almost one-
fifth of US men during their lifetime. Epidemiological
studies suggest that up to 5% of all cases may be due
to autosomal dominant genes [1–4], and twin studies
suggest that approximately 42% of PRCA cases dia-
gnosed under the age of 70 years are likely to be due to
heritable factors [5]. Men with an affected father or
brother are twice as likely to develop PRCA as men
with no affected relatives [6], and the relative risk of
developing PRCA rises considerably as the number of
cases in a family cluster increases and the average age at
diagnosis in the cluster decreases [7]. A meta-analysis
of PRCA risk amongmenwith a positive family history
found a 1.8–2.1-fold increased risk if a second degree
relative is affected compared to a 2.9-fold increased risk
if the father or a brother is affected [8]. The results from
the Breast Cancer Linkage Consortium (BCLC) showed
a RR of 4.65 (95% confidence interval, CI 3.48–6.22) of
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PRCA in male BRCA2 mutation carriers, data sup-
ported by a case–control study of 251 unselected
Ashkenazi Jewish PRCA cases and 1,472 controls
which estimated the odds ratio for PRCA in BRCA2
mutation carriers to be 4.78; 95% CI 1.87–12.25) [9].
Edwards et al. [10] screened the complete BRCA2
coding sequence in 263 British men under the age of
55 years and identified six truncating mutations (2.3%)
compared to aBRCA2mutationprevalence in theUKof
a round 0.13%. From these data, they estimated that
there was a 23-fold relative risk of developing prostate
cancer by age 56 years in BRCA2 mutation carriers.
Moreover, a recent Icelandic study has shown that
PRCA arising in BRCA2 mutation carriers has a
significantly worse prognosis compared to sporadic
PRCA [11].However, other groups have shown limited
[12] or no association [13,14] of BRCA2mutations with
familial PRCA.
PALB2/FANCN is a recently identified protein
which interacts closely with BRCA2 [15]. This inter-
action is essential for BRCA2 anchorage to nuclear
structures and for its function in double strand break
repair by homologous recombination [15]. Recent
studies have shown that, as with BRCA2, mutations in
PALB2 are a cause of hereditary breast cancer [16–18].
To date, there are no published studies on PALB2 in
other cancer types. In view of the close functional
relationship betweenPALB2 andBRCA2and their joint
role in breast cancer predisposition, it is conceivable
that PALB2 mutations may also predispose to PRCA
and that PALB2 mutations account for a proportion of
hereditary PRCA. We therefore screened PALB2 in a
cohort of highly selected PRCA families.
METHODS
Study Subjects
Subjects were selected from the University of
Michigan Prostate Cancer Genetics Project (PCGP), a
large, ongoing, family-based study of hereditary PRCA.
All participants gave written informed consent, and all
consents and protocols were approved by the Institu-
tional Review Board at the University of Michigan
Medical School. To be eligible for the PCGP, families
must have either two or more living members affected
with prostate cancer or at least one living member with
early onset PRCA (diagnosed at <55 years of age).
For each participant a blood sample was taken for
DNA extraction, the medical charts were reviewed and
extended family history information was obtained. For
the current study, 95 families with either multiple
cases of early onset PRCA (defined as diagnosis
prior to age 55 years) or a single case of early onset
PRCA and multiple (defined as five or more) cases of
PRCAdiagnosed at any agewere identified. Of those 95
families, 77 had two or more cases of early onset PRCA,
and the remaining 18 had one case of early onset PRCA
and five or more total cases of PRCA. The individual
with the youngest age of diagnosis for whomDNAwas
available was selected from each family for PALB2
sequencing. Characteristics of the families and indi-
viduals tested are given in Tables I and II, respectively.
PALB2 mutation analysis was performed by DNA
sequencing as previously described [18]. Primers were
designed to include an average of 75 base pairs either
side of each exon, and at the 50 and 30 ends of PALB2 the
analyzed sequence included 50 bases upstream of exon
1 (150 bases upstream of the translation start site) and
50 bases downstream of exon 13 (350 bases downstream
of the stop codon).
RESULTSANDDISCUSSION
Probands from a total of 95 hereditary prostate
cancer familieswere screened forPALB2mutations and
no truncating mutations were identified. A number of
sequence variants were detected, themajority of which
have been previously characterized [17] (Table III)
and therefore it seems unlikely that these contribute
to PRCA risk. Two previously unreported variants,
however, were identified, namely K18R and V925L.
Neither variant was located in a known functional
domain of PALB2, and both were classified as
‘‘tolerated’’ using SIFT [19]. The K18R variant was
found in the proband as well as his unaffected brother.
Moreover, this family is of African American descent
which most likely explains why the variant has not
been seen in the control group screened by Rahman
et al. [17], 97%percent ofwhichwere ofwhite ethnicity.
The V925L variant was detected in both the proband
and his affected brother. And as with K18R, no further
samples were available from other family members.
However as this amino acid change is relatively
conservative (Grantham score¼ 32), it seems unlikely
that it is pathogenic.
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Minimum age of diagnosis 48.8 [37–54]
Average age of diagnosisb 56.0 [52–60.3]
Number of early onset PRCA cases 2.0 [1–5]
Total number of PRCA cases 2.4 [2–13]
aNumber of families and (percentage of total families) are given.
bMedian and [interquartile range] are given.
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Our studywasdesigned todeterminewhether ornot
PALB2 is a moderate to high penetrance gene in PRCA
by screening families that were highly enriched for
hereditary characteristics including early age at cancer
diagnosis and/or multiple affected family members.
Note that in this report,menwhowere tested forPALB2
mutations had a median age of prostate cancer
diagnosis of 49 years, which is approximately 20 years
earlier than the median age of diagnosis for sporadic
PRCA.We specifically selected families from the PCGP
resource with early-onset PRCA based on the findings
of Edwards et al. [10]. These investigators screened
265menwith PRCAdiagnosed at or before age 55 years
for BRCA2mutations and identified 6 men (2.3%) with
protein truncating mutations. BRCA2 and PALB2,
together with BRCA1-interacting protein (BRIP1 or
FANCJ), comprise Group III Fanconi Anemia (FA)
proteins [20]. These proteins appear to act downstream
from the ID complexwhich is formed fromGroup II FA
proteins FANCD2 and FANCI. Monoallelic mutations
in all three Group III FA genes are associated with
breast cancer susceptibility [21–23]. In our study we
screened sufficient familial cases to have an 85%
probability of detecting at least one deleterious
mutation if the expected PALB2 carrier rate is 2%. This
frequency is not unreasonable given that 1) our families
werehighly selectedandenriched specifically for early-
onset PRCA, and 2) the BRCA2 mutation frequency
from Edwards et al. [10] in sporadic young onset
prostate cancer was 2.3%.
In their recent study Erkko et al. [16] screened
475 unselected and 164 familial (defined as having at
least two affected members) PRCA cases, all from
Finland, for the PALB2 1592delT founder mutation.
The mean age at diagnosis in the study group was
69.5 years. They identified the mutation segregating
in one family with four PRCA cases, average age at
diagnosis 73.5 years. These data suggest that PALB2
may be implicated in hereditary PRCA in Finnish
PRCA families. However, this does not seem to be the
case in similar types of PRCA families in North
America. Such geographical variation has been pre-
viously seenwith other genetic variants such asCHEK2
1100delCwhichwas found to be at increased frequency
in PRCA cases from Poland [24] and Finland [25] but
not southern Sweden [26]. While it is unlikely that
PALB2mutations play amajor role hereditary PRCA, it
may still be possible that deleterious PALB2mutations
predispose toPRCA in some rare families.However, no
familial PRCA studies have shown evidence of linkage
to the PALB2 locus on 16p12. It remains possible that
common variants in PALB2 could be associated with a
slightly increased risk for PRCA, but this studywas not
designed to identify such an effect.
A number of other candidate genes have been
studied in hereditary prostate cancer, but BRCA2 is
the only gene that has been shown to cause an increased
risk of prostate cancer inmultiple studies [7].While the
results of our study indicate that deleteriousmutations
in PALB2 do not significantly contribute to hereditary
PRCA, it remains possible that other genes coding
for proteins associated with BRCA2 are potential
PRCA-predisposition genes.
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TABLE II. Characteristics of Individuals Resequenced
(n¼ 95)
Trait No. (%)
Age at diagnosisa 49.0 [47–52]
Pre-diagnosis PSAa 7.7 [4.0–7.5]





Column subtotals do not sum to 95 due to missing data.
aMedian and [interquartile range] are given.





2 K18R 1 SIFT: tolerated
4 L303L 1 Silent
L337S 4 Previously reported [17]
I309V 1 Previously reported [17]
Q559R 15 Previously reported [17]
S524S 1 Previously reported [17]
5 E672Q 4 Previously reported [17]
G752G 1 Silent
8 V925L 1 SIFT: tolerated
9 G998E 2 Previously reported [17]
12 T1100T 2 Previously reported [17]
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